Sens. Urge Watchdogs To Inspect $53B Valeant-Allergan Play
More than a half-dozen U.S. senators have asked competition regulators to review the buzzed-about $53 billion merger proposal that would fold Botox maker Allergan Inc. into Valeant Pharmaceuticals International Inc., saying...To view the full article, register now.
Already a subscriber? Click here to view full article